Your browser doesn't support javascript.
loading
Overcoming resistance against HER2-targeting agents in fifth-line therapy: is there still a place for bevacizumab in HER2+ breast cancer?
Huemer, Florian; Gampenrieder, Simon Peter; Schlattau, Alexander; Greil, Richard.
Affiliation
  • Huemer F; Third Medical Department with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medic
  • Gampenrieder SP; Third Medical Department with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medic
  • Schlattau A; Department of Radiology, Paracelsus Medical University Salzburg, Salzburg, Austria.
  • Greil R; Third Medical Department with Hematology, Medical Oncology, Hemostaseology, Infectious Diseases and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute with Laboratory of Immunological and Molecular Cancer Research and Center for Clinical Cancer and Immunology Trials, Paracelsus Medic
Clin Breast Cancer ; 14(1): e17-20, 2014 Feb.
Article in En | MEDLINE | ID: mdl-24246725
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Carcinoma, Intraductal, Noninfiltrating / Receptor, ErbB-2 / Angiogenesis Inhibitors / Vascular Endothelial Growth Factor A / Antibodies, Monoclonal, Humanized Limits: Female / Humans / Middle aged Language: En Journal: Clin Breast Cancer Journal subject: NEOPLASIAS Year: 2014 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Carcinoma, Intraductal, Noninfiltrating / Receptor, ErbB-2 / Angiogenesis Inhibitors / Vascular Endothelial Growth Factor A / Antibodies, Monoclonal, Humanized Limits: Female / Humans / Middle aged Language: En Journal: Clin Breast Cancer Journal subject: NEOPLASIAS Year: 2014 Document type: Article Country of publication: United States